Johnson & Johnson temporarily halts Covid-19 vaccine output: report
NYSE - LSE
| GSK | 0.76% | 40.355 | $ | |
| RYCEF | -1.64% | 15.25 | $ | |
| VOD | -0.94% | 11.66 | $ | |
| BTI | 0.39% | 56.01 | $ | |
| RIO | -0.65% | 63.03 | $ | |
| CMSC | -0.25% | 24.329 | $ | |
| RELX | 0.89% | 47.11 | $ | |
| BP | -0.38% | 34.3 | $ | |
| AZN | 0.17% | 77.69 | $ | |
| NGG | 0.42% | 71.18 | $ | |
| BCC | -2.29% | 80.545 | $ | |
| JRI | -0.51% | 13.85 | $ | |
| CMSD | 0.39% | 24.556 | $ | |
| BCE | 0.3% | 23.5 | $ | |
| SCS | -0.85% | 16.738 | $ | |
| RBGPF | 0% | 77.27 | $ |
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.
J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.
"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.
J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.
L.Bohannon--NG
